Petit mal epilepsy – European Clinical Trials Information Network

Study on the Long-Term Safety of Brivaracetam for Children and Young Adults with Childhood or Juvenile Absence Epilepsy

Wed, 29 Apr 2026 15:01:39 +0000

This clinical trial is focused on studying the long-term safety and tolerability of a medication called brivaracetam in individuals with Childhood Absence Epilepsy or Juvenile Absence Epilepsy. These are types of epilepsy that typically begin in childhood or adolescence and are characterized by brief, sudden lapses in attention or staring spells. The medication being tested, brivaracetam, is available in two forms: a film-coated tablet and an oral solution. It is designed to help manage symptoms associated with these types of epilepsy.

The purpose of the study is to evaluate how safe and well-tolerated brivaracetam is when used over a long period. Participants in the study will receive brivaracetam and will be monitored for any side effects or adverse reactions that may occur during the treatment. The study will also look at how often these side effects lead to participants stopping the medication. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered.

Participants will take brivaracetam for a maximum period of 36 months. Throughout the study, researchers will collect information on any side effects experienced by the participants, including any serious adverse events. This information will help determine the long-term safety of brivaracetam for treating Childhood Absence Epilepsy and Juvenile Absence Epilepsy. The study aims to provide valuable insights into the use of brivaracetam for managing these conditions in children and young adults.

Study on Fast Sedation with Propofol and Midazolam vs. Anti-Seizure Drug Combination for Treating Refractory Status Epilepticus in Intensive Care Patients

Wed, 29 Apr 2026 14:59:33 +0000

This clinical trial is focused on studying a condition known as status epilepticus, which is a severe and prolonged seizure that can be life-threatening. The study aims to compare two different treatment approaches for this condition. One approach involves using high doses of medications that help control seizures, known as antiseizure medications. The specific medications being studied include Levetiracetam, Sodium Valproate, Fosphenytoin Sodium, Topiramate, Lacosamide, and Brivaracetam. These medications are administered intravenously, meaning they are given directly into a vein. The other approach involves using medications for rapid sedation, which help calm the brain and body. The medications used for sedation in this study are Propofol and Midazolam, also given intravenously.

The purpose of the study is to determine the effectiveness of rapid sedation with Propofol or Midazolam in an intensive care setting compared to intravenous antiseizure treatment in a hospital ward for patients with a specific type of status epilepticus that is resistant to initial treatments. This type of status epilepticus is referred to as non-convulsive status epilepticus, where the seizures are not accompanied by the typical convulsions or shaking. The study will involve monitoring patients over a period to see how well each treatment works in stopping the seizures and to observe any side effects or complications that may arise.

Participants in the study will receive either the antiseizure medications or the sedation medications, and their progress will be closely monitored by medical professionals. The study will assess various outcomes, such as the number of patients whose seizures continue after 24 hours, any new neurological issues that arise, the length of hospital stay, and overall survival rates after treatment. The goal is to find the most effective and safe treatment option for managing this serious condition.

Study of brivaracetam as a treatment for childhood and juvenile absence epilepsy in patients aged 2-25 years

Wed, 29 Apr 2026 14:29:14 +0000

This clinical trial focuses on studying two types of epilepsy: Childhood Absence Epilepsy and Juvenile Absence Epilepsy. These conditions cause brief periods where a person loses awareness of their surroundings and appears to stare blankly into space. The study will test a medication called brivaracetam (oral solution) to see if it works and is safe for patients between 2 and 25 years of age.

The study will examine how well brivaracetam works when used as the only medication for treating these types of epilepsy. Some participants will receive brivaracetam while others will receive a placebo. The study uses a two-stage design, where after the initial treatment period, some participants who responded well to the treatment will enter a withdrawal phase to further confirm the medication’s effectiveness.

The main goal is to find out if brivaracetam can help control absence seizures, which are episodes where a person briefly loses awareness. The study will monitor participants using electroencephalogram (a test that records brain wave patterns) and track how often seizures occur. Throughout the study, researchers will also watch for any side effects to ensure the medication is safe for use in young patients.